fat reduction

Aesthetic Devices: Focus on the Body

Noninvasive body contouring and fat reduction treatments are driving patients to aesthetic practices and spurring new innovations.
MedEsthetics April 2019

A recent report from Axiom Market Research and Consulting Group forecasts 8 percent growth in body contouring procedures in the next five years, with the greatest rise occurring in noninvasive and minimally invasive techniques. This is not surprising to many practitioners who have witnessed the soaring popularity of CoolSculpting (cryolipolysis), the first noninvasive fat-reduction device approved by the U.S. Food and Drug Administration back in 2010.

Shape Shifting

Physicians share their experiences with the growing range of noninvasive fat reduction technologies.
Image: a sculpture of a woman's torso

In the five years since Zeltiq’s CoolSculpting device first received U.S. Food and Drug Administration (FDA) approval for the noninvasive destruction of fat in the abdomen, the medical aesthetics industry has seen an array of FDA-cleared fat reduction technologies enter the market. Each is designed to permanently thin down thighs, blast away back flab, whittle middles or slim chin chub with minimal or no downtime.

CoolSculpting Cleared To Treat Upper Arm Fat

Image of a woman pinching her upper arm fat

The U.S. Food and Drug Administration (FDA) has cleared CoolSculpting (Zeltiq Aesthetics) for the upper arms, adding to its previous clearances for the treatment of fat bulges in the submental area, thigh, abdomen, flank, bra and back fat area, and underneath the buttocks. CoolSculpting is a nonsurgical procedure that selectively reduces unwanted fat using a patented cooling technology. It works by gently cooling targeted fat cells in the body to induce a controlled elimination of fat cells without affecting surrounding tissue.

Next-Generation BTL Vanquish ME for Fat Reduction

A study published in the Journal of Drugs in Dermatology (December 2016) found that the BTL Vanquish ME (Maximum Energy) from BTL Aesthetics was effectively redesigned for more efficient and homogenous energy delivery to targeted tissue, reducing 53% more fat versus the BTL Vanquish. The BTL Vanquish ME, which debuted in 2015, is FDA-cleared for the circumferential reduction of the abdomen and thighs.

UltraShape Power Cleared for Fat Destruction

UltraShape Power Cleared for Fat Destruction

The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical’s UltraShape Power for noninvasive reduction of abdominal circumference via fat cell destruction. The device uses focused, pulsed mechanical ultrasound to target and destroy fat with a proprietary pulse structure that allows for fat destruction without damaging surrounding blood vessels, nerves and muscles. UltraShape Power includes a new transducer, which is lighter and delivers 20% more energy than its predecessor. In a recent clinical study, it demonstrated a 32% reduction in subcutaneous fat thickness.

Neothetics Announces Unsatisfactory LIPO-202 Trial Results

Neothetics has announced results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 (injectable salmeterol xinafoate) for the reduction of central abdominal bulging due to subcutaneous fat. The Phase 3 trials were randomized, double blind and placebo controlled, designed to assess the efficacy, safety and tolerability of LIPO-202 (total weekly dose of 0.4mcg for eight weeks) for the reduction of central abdominal bulging. The trials enrolled a total of 1,584 subjects who were randomized 1:1 to LIPO-202 or placebo.

Laser Lipolysis

Main Image: 
Laser Lipolysis

The SculpSure platform from Cynosure has received 510(k) clearance for noninvasive fat reduction. SculpSure is the first hyperthermic laser treatment approved for noninvasive lipolysis of the flanks and abdomen. The hands-free device features a 1060nm laser and a flexible applicator system to disrupt subcutaneous fat cells in approximately 25 minutes with no downtime. Contact: 888.523.2233, www.cynosure.com.

No, don't share this with BeautyEtc

CoolSculpting FDA Cleared for Submental Fat

CoolSculpting FDA Cleared for Submental Fat

ZELTIQ Aesthetics has received an expanded clearance for submental fat from the U.S. Food and Drug Administration (FDA) in conjunction with the release of its CoolMini applicator—designed to administer CoolSculpting cryolipolysis treatments to smaller pockets of fat, including submental fat. The new applicator’s size, shape and curvature is designed to comfortably fit small, problem areas. Patients may see results as early as three weeks, with the most dramatic results generally observed one to three months following treatment.

Cryolipolysis Effective for Pseudogynecomastia

Cryolipolysis Effective for Pseudogynecomastia

In a study published in Dermatologic Surgery (September 2015), Girish S. Munavalli, MD, MHS, and Ratchathorn Panchaprateep, MD, PhD, investigated the safety and efficacy of cryolipolysis for the nonsurgical treatment of pseudogynecomastia.

Twenty-one men with pseudogynecomastia were enrolled and received an initial 60-minute cryolipolysis cycle followed by a two-minute massage, and a second 60-minute cycle with 50% treatment area overlap. At the 60-day follow-up, subjects underwent another 60-minute treatment.